In this concise Medical Minute video, gain expert insights on the clinical trial data supporting the use of tirzepatide to improve outcomes in persons with T2D.
Gain expert insights on the clinical trial data supporting the use of tirzepatide to improve outcomes in persons with T2D.
The dual GIP/GLP-1 receptor agonist has demonstrated efficacy in lowering A1C and body weight in the phase III SURPASS trials. Here’s my take on how it may fit into the treatment toolbox for type 2 diabetes.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.